Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a
biomedical innovation company developing transformational
therapeutic devices targeting major medical conditions, announced
today the appointment of three new members to its Strategic
Advisory Board (“SAB”). Joining the Company’s SAB is Gary J.
Pruden, former Worldwide Chairman for Johnson & Johnson Medical
Devices Group; Eric A. Rose, M.D., Executive Chairman of SIGA
Technologies (Nasdaq: SIGA) and world-renowned cardiac surgeon and
scientist; and Jason Aryeh, a life sciences investment fund manager
and pharmaceutical industry expert who serves on the Board of
Directors of Ligand Pharmaceuticals, Inc. (Nasdaq: LGND).
“Our core business objective is to fully realize
the clinical and commercial value of our high impact,
evidence-based product innovations through strategic collaborations
with established market leaders. Our Strategic Advisory Board is a
key extension of Orchestra’s knowledge, perspective and
relationships with the medical device and biopharma industries. We
are honored to welcome these distinguished individuals to the ranks
of an already outstanding group,” stated David Hochman, Chairman of
the Board and Chief Executive Officer of Orchestra BioMed. “We
firmly believe that the experience and expertise that Gary, Eric
and Jason have amassed over the course of their careers will be
essential to our near- and long-term success as we execute on our
development plans of our portfolio, specifically Virtue® SEB and
BackBeat® CNT, two products that have the potential to address
significant unmet medical needs in cardiovascular disease and
hypertension.”
“I am honored and excited to work with Orchestra
BioMed’s exceptional executives and esteemed board of advisors,”
said Mr. Aryeh. “Orchestra’s late-stage programs, Virtue® SEB
and BackBeat® CNT, have the potential to save many lives,
offer profound health economic benefits, and be transformational
and disruptive in two of the largest, most established medical
device markets. I look forward to bringing my perspective,
particularly my strategically relevant experience from Ligand, to
Orchestra’s cutting-edge innovation, strategic partnering
and high-margin, cash flow focused business model.”
New Strategic Advisor
Biographies
Gary Pruden is a proven
industry leader with a broad background in technology and
pharmaceutical innovation and M&A transactions. Over the course
of his 32-year career at Johnson and Johnson (NYSE: JNJ), Mr.
Pruden held numerous senior leadership positions across both the
medical devices and pharmaceutical sectors. As the Worldwide
Chairman of the Medical Device group, he led a global business
where new technologies, global expansion and focus on the patient
were keys to success. He currently serves as a member of the Board
of Directors of Motus GI Holdings, Inc. (Nasdaq: MOTS), an
Orchestra-founded company. During his career at J&J, Mr. Pruden
led a large global business with a significant portion of sales
coming from outside of the United States including a strong focus
on emerging markets. During his time at J&J, Mr. Pruden also
helped lead the strategic collaboration with Google that was
established for the advancement of surgical robotics. He has
extensive experience in portfolio management including two large
divestitures (Cordis Corporation and Codman Neurosurgery) and exits
of non-strategic businesses, quality and compliance, as well as
global regulatory experience. Additionally, Mr. Pruden serves as an
Independent Director of Lantheus Holdings, Inc. (Nasdaq: LNTH).
Eric A. Rose, M.D. is a
world-renowned innovative surgeon and scientist, best known for
making history in 1984 when he performed the landmark achievement
of the first successful pediatric heart transplant. Over the course
of his career, he has continued to study and improve cardiac
surgical care in children and adults. He currently serves as the
Executive Chairman of the Board of Directors of SIGA Technologies,
Inc. (Nasdaq: SIGA), a commercial-stage pharmaceutical company
focused on serious unmet medical needs and
biothreats. Previously, he had served as Chairman and CEO of
SIGA. Dr. Rose chaired the Department of Health Evidence &
Policy at the Mount Sinai School of Medicine from 2008 to 2012.
From 1994 through 2007, he served as Chairman of the Department of
Surgery and Surgeon-in-Chief of the Columbia Presbyterian Center of
New York Presbyterian Hospital. In addition to his roles at SIGA,
Dr. Rose holds a position as Executive Vice President – Life
Sciences at MacAndrews & Forbes Incorporated, the holding
company of Ronald O. Perelman and a related party to SIGA. In 2010,
Dr. Rose became a director of Abiomed, Inc. (Nasdaq: ABMD), a
leading provider of medical devices that provide circulatory
support. In April 2013, he became a director for Mesoblast Inc.
(Nasdaq: MESO), an advanced cellular medicine company, where he
serves as Chairman of the Scientific and Technology Committee. Over
the course of his career, Dr. Rose has authored or co-authored more
than 300 peer-reviewed publications on topics such as
cardiovascular surgery, ventricular assist devices, and cardiac
transplantation, and he is the author of two books: Management of
End-Stage Heart Disease and Second Opinion: The Columbia
Presbyterian Guide to Surgery. Throughout his career, he has been
involved in grants totaling more than $25 million in funding,
including, a large National Heart, Lung, and Blood Institute
project, the Human Biology of Long-Term Mechanical Circulatory
Support.
Jason Aryeh is a
life sciences investment fund manager and pharmaceutical
industry expert with over twenty years of equity investment
experience in the life sciences sector. Mr. Aryeh is the
Founder and managing General Partner of JALAA Equities, LP, a
private hedge fund focused on the biotechnology and medical device
sectors and has served in such capacity since 1997. He has
also served as a member of the Board of Directors of Ligand
Pharmaceuticals, Inc. (Nasdaq: LGND), a biopharmaceutical company
focused on developing or acquiring technologies that help
pharmaceutical companies discover and develop
medicines and has served as Ligand’s Chairman of its
Nominating and Governance Committee since September 2006. Mr.
Aryeh is also a member of the Advisory Board of the
Accreditation Council for Medical Affairs (ACMA), an
internationally recognized accrediting body which focuses on
properly educating, training and credentialing pharmaceutical
and medical device industry sales representatives and medical
science liaisons. As a shareholder-focused advocate, Mr. Aryeh
has served on ten corporate or charitable foundation
boards.
Existing Strategic Advisory Board
Members
John R. Barr has spent his
career in medical devices and most recently served as Chief
Executive Officer at Surgical Specialties Inc., a privately held
medical device firm specializing in wound closure and surgical
knives that was sold to a private equity investor group in March
2017. Prior to that, he served as Executive Vice President and
President of Global Surgical at Bausch & Lomb Holdings
Incorporated until its acquisition by Valeant Pharmaceuticals in
August 2013.
Eric S. Fain, M.D. is the
President and Chief Executive Officer of Procyrion, a company
focused on the treatment of heart failure through the development
of a safe and innovative percutaneous mechanical circulatory
support (pMCS) device. He is the former Senior Vice President and
Group President, Cardiovascular and Neuromodulation at Abbott
following its acquisition of St. Jude Medical. Dr. Fain became
Group President of St. Jude Medical in 2014 where he was
responsible for global sales, marketing and clinical affairs across
the entire St. Jude Medical portfolio worldwide.
David Pacitti is President of
Siemens Medical Solutions, Inc. and Head of Siemens Healthineers
North America. Mr. Pacitti is responsible for leading the
marketing, sales, service, and support functions in the U.S., with
additional oversight of Canada, across the entire Healthcare
portfolio, including medical imaging, laboratory diagnostics,
therapy solutions, and services. Prior to joining Siemens in 2015
in his current role, Mr. Pacitti was Division Vice President of
U.S. Commercial Operations, Sales, and Marketing at Abbott Vascular
for two years, overseeing the company’s business in North
America.
Louis Shapiro is President and
CEO of Hospital for Special Surgery (“HSS”). He has served in this
role since October 2006, overseeing all strategic and operational
aspects of HSS and fulfilling its mission to advance the field of
musculoskeletal medicine through world-class patient care, research
and education. Under Mr. Shapiro’s leadership, HSS has experienced
significant growth, expansion of facilities and recognition as the
world leader in its specialty areas of orthopedics, rheumatology
and their related disciplines. Mr. Shapiro has more than 30 years
of healthcare experience, including as Executive Vice President and
Chief Operating Officer of Geisinger Health System in Pennsylvania,
and as a leader in the healthcare practice at McKinsey &
Company.
About Orchestra BioMed™
Orchestra BioMed, Inc. is a biomedical
innovation company focused on developing high impact, high value,
evidence based therapeutic solutions for medical procedures that
address major medical conditions, such as cardiovascular disease
and hypertension, that affect large patient populations and drive a
significant portion of healthcare costs. Orchestra BioMed’s
business strategy is to leverage partnerships with established
global market leaders to optimize the clinical impact and
commercial value of its products. Orchestra BioMed expects to
generate long-term, high margin cash flow from royalties, revenue
sharing, and licensing and development payments from strategic
partners that secure commercial rights to Orchestra
BioMed-developed products. Orchestra BioMed’s core innovation
and development expertise is in the areas of drug delivery,
interventional devices, bioelectronics and neuromodulation. The
Company’s lead cardiovascular therapies, which were developed from
concept stage by Orchestra BioMed’s wholly-owned subsidiaries, are
highly proprietary and have demonstrated promising clinical results
in addressing specific high-need patient populations with artery
disease and hypertension. The Virtue® Sirolimus-Eluting Balloon
(SEB), is a novel, first in-class device that delivers
delayed-release bioabsorbable particle encapsulated Sirolimus, the
proven gold-standard drug for preventing restenosis of treated
arteries, to the vessel wall during balloon angioplasty without the
need for a permanent implant. BackBeat® Cardiac Neuromodulation
Therapy (CNT), is a patented implantable cardiac stimulation-based
treatment for hypertension that immediately and substantially
lowers blood pressure while simultaneously modulating autonomic
nervous system responses that normally drive and maintain blood
pressure higher.
Forward Looking Statements
Some of the statements made herein constitute
forward-looking statements. These statements relate to future
financial and other performance or anticipated plans and are
identified by words such as “may,” “will,” “should,” “expect,”
“could,” “scheduled,” “plan,” “intend,” “anticipate,” “believe,”
“estimate,” “potential,” “propose” and “continue” or negative
variants of such terms. These and similar forward-looking
statements discuss the Company’s future expectations and plans. The
Company operates in a very competitive and rapidly changing
environment. New risks emerge from time to time. Given these risks
and uncertainties, the Company cautions against placing undue
reliance on these forward-looking statements. These statements are
only estimates of future performance. Actual performance or events
may not meet such expectations or estimates and may, in fact,
differ materially.
Although the Company believes that the
expectations reflected in the forward-looking statements made
herein are reasonable, the Company cannot and does not guarantee
future results, levels of activity, performance or achievements.
Moreover, the Company does not assume any responsibility for the
accuracy and completeness of such forward-looking statements in the
future. The Company does not plan and, subject to applicable law,
undertakes no obligation to update any of the forward-looking
statements made herein after the date hereof in order to conform
such statements to actual results.
Investor and Media Contact:
Jenene Thomas Communications, LLCJenene
Thomas(833) 475-8247OBIO@jtcir.com
Source: Orchestra BioMed, Inc.
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Apr 2023 to Apr 2024